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Background: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver
disease where liver biopsy remains the gold standard for diagnosis. Here we aimed
to evaluate the role of circulating adiponectin, leptin, and insulin-like growth factor
1 (IGF-1) levels as non-invasive NAFLD biomarkers and assess their correlation with
the metabolome.
Materials and Methods: Leptin, adiponectin, and IGF-1 serum levels were measured
by ELISA in two independent cohorts of biopsy-proven obese NAFLD patients and
healthy-liver controls (discovery: 38 NAFLD, 13 controls; validation: 194 NAFLD,
31 controls) and correlated with clinical data, histology, genetic parameters, and
serum metabolomics.
Results: In both cohorts, leptin increased in NAFLD vs. controls (discovery: AUROC
0.88; validation: AUROC 0.83; p < 0.0001). The leptin levels were similar between
obese and non-obese healthy controls, suggesting that obesity is not a confounding
factor. In the discovery cohort, adiponectin was lower in non-alcoholic steatohepatitis
(NASH) vs. non-alcoholic fatty liver (AUROC 0.87; p < 0.0001). For the validation
cohort, significance was attained for homozygous for PNPLA3 allele c.444C (AUROC
0.63; p < 0.05). Combining adiponectin with specific serum lipids improved the assay
performance (AUROC 0.80; p < 0.0001). For the validation cohort, IGF-1 was lower with
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advanced fibrosis (AUROC 0.67, p< 0.05), but combination with international normalized
ratio (INR) and ferritin increased the assay performance (AUROC 0.81; p < 0.01).
Conclusion: Serum leptin discriminates NAFLD, and adiponectin combined with
specific lipids stratifies NASH. IGF-1, INR, and ferritin distinguish advanced fibrosis.
Keywords: adiponectin, circulating biomarkers, fibrosis, IGF-1, leptin, lipid metabolism, NAFLD
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is one of the most
prevalent chronic liver conditions and an important risk
factor for liver cirrhosis and hepatocellular carcinoma. The
NAFLD spectrum varies from simple fat accumulation to non-
alcoholic steatohepatitis (NASH), characterized by hepatocellular
injury, inflammation, and, eventually, fibrosis (1). In fact, the
increasing prevalence of NAFLD parallels that of obesity and
is accompanied by rising liver-related morbidity and mortality
and, consequently, increased socio-economic burden (2). Clinical
practice guidelines recommend NAFLD screening in individuals
with metabolic risk factors, such as obesity, type 2 diabetes, and
hypertension (metabolic syndrome) (3, 4). Most NAFLD patients
are clinically asymptomatic, and when present, the symptoms are
unspecific and associated with advanced disease. Furthermore,
liver function tests may be within normal range or only
slightly increased. Thus, panels composed by anthropometric
and blood biochemistry data have been proposed to assess hepatic
steatosis (fatty liver index, hepatic steatotic index, NAFLD
liver fat score, SteatoTest), although with modest performance
compared with imaging biomarkers. In turn, imaging techniques
[ultrasonography, magnetic resonance imaging (MRI)] are not
fully conclusive at identifying liver inflammation and hepatocyte
injury typical of NASH or distinguishing NASH from fatty liver
(3, 4). Indeed differential diagnosis between non-alcoholic fatty
liver (NAFL) and NASH is an important indicator of increased
risk of cirrhosis and other hepatic co-morbidities, although the
stage of fibrosis is increasingly recognized as the most relevant
NASH prognostic marker (5).
Caspase-3-generated cytokeratin-18 is the most studied
biomarker for NASH diagnosis but has limited sensitivity for
NASH stage screening (6); hence, other putative biomarkers
(inflammatory markers, adipokines, and others) are emerging
(7). In parallel, biomarker panels combining several blood
Abbreviations: ALT, alanine aminotransferase; AHT, arterial hypertension; APRI,
AST/platelet ratio index; AST, aspartate aminotransferase; AUROC, area under the
ROC curve; DG, diglycerides; DHA, docosahexaenoic; ELF, enhanced liver fibrosis;
ELISA, enzyme-linked immunosorbent assay; FA, fatty acids; Fib-4, fibrosis-4
index; GGT, gamma-glutamyl transferase; HDL, high-density lipoprotein; IGF-1,
insulin-like growth factor 1; INR, international normalized ratio; LDL, low-density
lipoprotein; LPC, lysophosphatiylcholines; LPE, lysophosphatidylethanolamines;
LPI, lysophosphatidylinositols; MRI, magnetic resonance imaging; NAFL,
non-alcoholic fatty liver; NAFLD, non-alcoholic fatty liver disease; NAS,
NAFLD activity score; NASH, non-alcoholic steatohepatitis; NFS, NAFLD
fibrosis score; NPV, negative predictive value; PC, phosphatidylcholines; PE,
phosphatidylethanolamines; PI, phosphatidylinositols; PPV, positive predictive
value; ROC, uniparameter receiver operating characteristic; SM, sphingomyelin;
TG, triglycerides.
parameters are being proposed for fibrosis staging, such as
aspartate aminotransferase (AST) to alanine aminotransferase
(ALT) ratio, AST/platelet ratio index (APRI), fibrosis-4 index
(Fib-4), or FibroTest, but accuracy has been limited as they
mostly rely on liver injury markers (8). To date, liver biopsy is
the gold-standard method to accurately discriminate NAFL from
NASH, to evaluate the extent of tissue damage and fibrosis, and
to rule out other etiologies. However, this is an expensive and
invasive procedure with potential for serious complications (9).
Moreover, liver biopsy lacks the ability to provide a complete
3D liver overview and is limited by sampling variability. Hence,
identification and validation of simple, specific, reproducible, and
non-invasive biomarkers that accurately diagnose and monitor
NAFLD patients constitute an urgent unmet medical need.
NAFLD is generally regarded as a hepatic manifestation of
metabolic syndrome (10). Although not yet fully understood,
the disease pathogenesis involves disturbances in adipose tissue,
insulin resistance, and inflammation (11). Thus, adipokines’ and
related cytokines’ role in NAFLD pathogenesis and severity has
been equated (12), and their potential as non-invasive biomarkers
of diagnosis and staging deserves further investigation.Moreover,
lipid and metabolite signatures in plasma and in liver tissue
associated with NAFLD and/or fibrosis (13–15) may further
support non-invasive NAFLD diagnosis (16).
We hypothesize that serum adipokines—leptin and
adiponectin—and liver-produced insulin-like growth factor
1 (IGF-1) are useful circulating biomarkers for NAFLD
diagnosis and stratification. We assessed their potential as
non-invasive biomarkers in the discovery and validation cohorts




Human serum samples were collected from two independent
cohorts of morbidly obese adult patients with biopsy-proven
diagnosis of NAFLD, who were undergoing bariatric surgery
[body mass index (BMI) ≥35 kg/m2], and healthy-liver
individuals (17) (BMI <35 kg/m2) from Santa Maria Hospital
(Lisbon, Portugal; discovery cohort) and Donostia University
Hospital (San Sebastian, Spain; validation cohort). Up to 20%
of the patients were taking statins. The patient inclusion criteria
consisted in liver biopsy-proven NAFLD diagnosis and BMI≥35
kg/m2. The exclusion criteria included alcohol consumption≥20
(females) or ≥30 g/day (males), viral hepatitis B and C, and
other causes of chronic liver disease. The liver biopsies were
obtained during bariatric surgery, under standard procedures.
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Fibrosis was assessed from a distance >0.5 cm from the liver
capsule. Blood and tissue samples were collected at a maximum
of 1-week interval, while liver imaging was performed within
24 h of surgery. Sample collection was performed after receipt
of the patient’s informed consent and the Institutional Review
Board’s approval, in accordance with the Declaration of Helsinki.
For histology purposes, formalin-fixed paraffin-embedded tissue
sections were routinely stained with hematoxylin–eosin method
and with Masson’s trichrome for fibrosis evaluation. Histological
evaluation was performed by experienced pathologists in a
blinded fashion following agreement on the histological features
of NAFLD/NASH assessment and NASH diagnosis. NAFLD
activity score (NAS 0–8) and fibrosis stage (F0–4) were assigned
to each biopsy according to the NASH Clinical Research
Network histological scoring system (18). Fibrosis extent was
dichotomized as early (F0–2) and advanced (F3–4) fibrosis.
Where possible, fibrosis scores APRI (19), Fib-4 (20), and
NAFLD fibrosis score (NFS) (21) were calculated. Individuals
were classified as healthy non-obese controls (BMI <35 kg/m2),
healthy obese controls [BMI ≥35 kg/m2, maximum NAS = 1 (if
steatosis= 0) andmaximumfibrosis score= 1], NAFL (NAS≤4),
or NASH (NAS ≥5). Liver biopsies were obtained from healthy
non-obese individuals that were referred for hepatic surgery
without an underlying liver disease (17).
The discovery cohort (n = 51) included three groups: healthy
non-obese controls (n = 13), NAFL (n = 26), and NASH
patients (n= 12). Routine biochemical parameters were available;
however, detailed histological data was not fully disclosed.
The validation cohort (n = 225) encompassed four groups:
healthy non-obese controls (n = 20), healthy obese controls
(n= 11), NAFL (n= 100), and NASH patients (n= 94). Routine
biochemical parameters were available, and detailed histological
data is described in Supplementary Table 1. Information on
co-morbidities (arterial hypertension, diabetes, dyslipidemia,
and cholelithiasis), genetic polymorphisms [PNPLA3 rs738409
(c.444C>G, p.I148M), MBOAT7 rs641738 (c.50G>A, p.G17E),
and TM6SF2 rs58542926 (c.449C>T, p.E167K)], liver hepatic
triglyceride (TG) content evaluation by Folch method (17) (n =
140), and imaging assessment of liver steatosis (MRI; n = 122)
were also available.
Serum Hormones and Data Analysis
The serum levels of leptin, adiponectin, and IGF-1 were
measured in single determination using specific enzyme-linked
immunosorbent assay kits according to the manufacturer’s
instructions (Mediagnost GmbH, Reutlingen, Germany) and
correlated with NAFLD activity score, fibrosis stage, biochemical
parameters, genotypes, imaging data, and co-morbidities. Data
analysis was first performed in the discovery cohort and then
expanded to the validation cohort. The normality of values
distribution was tested with Kolmogorov–Smirnov (n ≥ 50) or
Shapiro–Wilk (n< 50) tests. According to the normality of values
distribution, one-way ANOVA or Kruskal–Wallis test followed
by Bonferroni or Dunn’s multiple-comparison test were used
to determine differences between sample groups according to
NAS score, steatosis, lobular inflammation and ballooning stages,
and genotypes. Differences according to fibrosis dichotomy and
presence of co-morbidities were determined with unpaired t-
test or Mann–Whitney U-test. To correlate hormone serum
levels and biochemical parameters or imaging data, Pearson or
Spearman correlation coefficient and linear regression analysis
were applied. Uniparameter receiver operating characteristic
(ROC) curve analysis tested the hormones’ discriminatory power.
Cutoff values were retrieved from Youden index. Variables
presenting an area under the ROC curve (AUROC) value
superior to 0.60 and p <0.05 were selected for binomial
logistic regression analysis. Multi-parameter ROC curves were
established for relevant parameter combinations, where an
AUROC value >0.80 was considered a very good assay
performance. Associated sensitivity, specificity, and positive
predictive value (PPV) and negative predictive value (NPV)
were estimated. A p-value <0.05 was considered significant.
All statistical analysis were performed using GraphPad Prism,
version 8.0.2 (La Jolla, California, USA) and IBM SPSS Statistics,
version 26 (Armonk, New York, USA).
Metabolomic Analysis
Serum samples from 198 patients in the validation cohort
were randomly selected for metabolomic analysis by
liquid chromatography–time of flight–mass spectrometry.
Two separate liquid chromatography–time of flight–mass
spectrometry-based platforms were used: platform 1 to
analyze methanol lipid extracts [including fatty acids (FA),
acyl carnitines, bile acids, lysoglycerophospholipids, N-
acyl ethanolamines, and oxidized FA] and platform 2 for
methanol/chloroform lipid extracts (including glycerolipids,
cholesterol esters, sphingolipids, and glycerophospholipids)
(22). Quality control calibration and validation samples were
used to assess data quality. The spectra were mass-corrected
by reference to leucine enkephalin. System control and data
pre-processing were performed using Masslynx 4.1 software and
TargetLynx application manager (Waters Corp., Milford, USA).
Peak detection, noise reduction, and data normalization were
performed as previously described (23). For univariate analyses,
the samples were grouped according to the median serum level of
each hormone (leptin = 39.61 ng/ml; adiponectin = 4.84µg/ml;
IGF-1 = 103.65 ng/ml). Log2 fold change for metabolite levels
between higher than median vs. lower than median hormone
level groups was determined and compared using unpaired
Student’s t-test (p < 0.05) using R v.3.4.1 (R Development Core
Team, 2017; http://cran.r-project.org). A p-value <0.05 was
considered significant.
RESULTS
Clinical and Biochemical Features of
Patient Cohorts
In both cohorts, the NAFL and NASH patients were similar
with respecting to age, gender, BMI, gamma-glutamyl transferase
(GGT), serum glucose, triglycerides, and cholesterol [total, high-
density lipoprotein (HDL) or low-density lipoprotein (LDL)]
concentrations (Tables 1, 2). While in the discovery cohort
the NAFL and NASH patients had similar circulating AST
and ALT, in the validation cohort these liver injury markers
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Age (years) 38.38 ± 1.99 44.83 ± 2.68
Gender (M/F) 10/16 4/8
BMI (kg/m2 ) 44.68 ± 1.32 41.56 ± 1.27
Hematology and biochemistry
AST (U/L) 27.19 ± 2.55 30.92 ± 3.16
ALT (U/L) 39.62 ± 6.96 45.08 ± 5.38
GGT (U/L) 29.36 ± 4.22 37.58 ± 3.42
Glucose (mg/dl) 93.58 ± 2.13 100.58 ± 3.68
Triglycerides (mg/ml) 118.44 ± 5.82 155.91 ± 20.63
Total cholesterol (mg/ml) 191.27 ± 7.41 197.67 ± 10.83
HDL-cholesterol (mg/ml) 46.27 ± 2.69 44.08 ± 2.57
LDL-cholesterol (mmol/dl) 125.00 ± 7.61 125.73 ± 10.11
Total bilirubin (mg/dl) 0.69 ± 0.08 0.74 ± 0.08
Platelets (109/L) 280.42 ± 17.32 300.82 ± 11.70
INR 0.97± 0.01 0.94 ± 0.02
Data are expressed as mean ± SEM. Information not available for non-obese controls.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index;
F, female; GGT, γ-glutamyl transferase; HDL, high-density lipoprotein; INR, international
normalized ratio; LDL, low-density lipoprotein; M, male; NAFL, nonalcoholic fatty liver;
NASH, nonalcoholic steatohepatitis.
and liver fat content evaluated by magnetic resonance imaging
and Folch method were increased in NASH vs. NAFL (p <
0.05). The prevalence of co-morbidities was similar between
NAFL and NASH patients, except for dyslipidemia (higher
in NASH vs. NAFL; p < 0.05). PNPLA3 risk allele c.444G
frequency vs. wild-type allele was lower in both controls
(12.5 vs. 87.5%) and NAFLD (23.7 vs. 76.3%), consistent
with previous reports (24). Similarly to previous literature
(25), in NAFLD patients, TM6SF2 risk allele c.499T showed a
frequency of 5.7%, whileMBOAT7 risk allele c.50>A presented a
frequency of 45.7%.
Leptin Predicts NAFLD and Correlates With
Serum Content
The impact of BMI on leptin and its influence on liver fibrosis
remain controversial (26). We observed lower leptin levels in
men than in women (discovery cohort: 20.63 ± 3.57 vs. 40.63
± 4.00 ng/ml, p < 0.01; validation cohort: 25.8 ± 2.03 vs.
49.55 ± 1.99 ng/ml, p < 0.0001) as reported before (27). In
the discovery cohort, serum leptin was higher in NAFL (31.43
± 3.59 ng/ml, p < 0.01) and NASH (37.62 ± 5.12 ng/ml, p <
0.001) vs. in non-obese controls (8.92 ± 2.88 ng/ml), showing
a good performance when distinguishing non-obese controls
from NAFLD patients, with AUROC = 0.88 (95% CI, 0.77–0.98;
p < 0.0001) and an overall accuracy of 0.81 (95% CI, 0.68–0.91),
considering 25% disease prevalence (Figure 1A). By applying a
leptin cutoff value >9.33 ng/ml for NAFLD inclusion, the assay
sensitivity and specificity were 94 and 77%, respectively, and the
NPV for ruling out NAFLD diagnosis was 98% (Figure 1A). No
TABLE 2 | Patient demographic, clinical and laboratory data for validation cohort.
Parameter Obese controls NAFL NASH
Number 11 100 94
Age (years) 48.10 ± 2.86 45.20 ± 1.27 48.96 ± 1.67
Gender (M/F) 4/6 26/66 34/56
BMI (kg/m2) 46.03 ± 1.87 44.60 ± 0.67 45.89 ± 0.73
Hematology and biochemistry
AST (U/L) 23.78 ± 5.93 20.71 ± 0.92 26.24 ± 1.49a
ALT (U/L) 22.67 ± 3.43 25.68 ± 1.70 35.18 ± 2.21a
GGT (U/L) 21.14 ± 3.52 37.20 ± 4.78 42.27 ± 4.45
Glucose (mg/dl) 108.30 ± 6.77 113.65 ± 3.44 120.22 ± 3.39
Triglycerides
(mg/ml)
127.00 ± 32.44 142.22 ± 9.98 158.79 ± 8.43
Total cholesterol
(mg/ml)
198.25 ± 4.91 195.75 ± 4.08 206.79 ± 5.41
HDL-cholesterol
(mg/ml)
51.50 ± 4.84 48.58 ± 1.47 50.24 ± 1.45
LDL-cholesterol
(mmol/dl)
131.30 ± 8.31 118.38± 3.65 125.69 ± 4.12
Total bilirubin
(mg/dl)
0.54 ± 0.10 0.55 ± 0.09 0.48 ± 0.03
Platelets (109/L) 281.00 ± 33.57 267.78 ± 7.09 251.79 ± 6.22
Hemoglobin
(g/dl)
12.40 ± 0.61 13.73 ± 0.13 13.75 ± 0.21
Ferritin (ng/ml) 166.87 ± 31.14 114.15 ± 15.91 134.34 ± 19.79
Albumin (g/dl) 3.96 ± 0.27 4.28 ± 0.05 4.28 ± 0.06
INR 1.01 ± 0.02 0.97 ± 0.01 0.98 ± 0.01
Liver steatosis































Data are expressed as mean ± SEM. Information not available for non-obese controls.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index;
C, cytosine; F, female; G, guanine; GGT, γ-glutamyl transferase; HDL, high-density
lipoprotein; INR, international normalized ratio; LDL, low-density lipoprotein; M, male; MRI,
magnetic resonance imaging; n/a, not available; NAFL, nonalcoholic fatty liver; NASH,
nonalcoholic steatohepatitis; T, thymine.
ap <0.05 vs. NAFL.
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FIGURE 1 | Leptin serum levels allow to distinguish NAFLD. (A) In the discovery cohort, leptin levels were significantly higher in NAFL and NASH patients compared
with non-obese, healthy-liver controls, presenting an AUROC value of 0.88 when distinguishing controls (n = 13) from NAFLD patients (n = 36), with very high general
accuracy and NPV. (B) In the validation cohort, the leptin levels did not show differences among healthy controls, non-obese or obese, and confirmed increased levels
in NAFL and NASH. Leptin presented good performance assay results when distinguishing healthy controls (n = 31) from NAFLD (n = 194), with an AUROC value of
0.83 and overall accuracy of 0.60 when applied the cutoff value of >9.33 ng/ml leptin for NAFLD diagnosis established in the discovery cohort. (C) Main correlations
found between leptin and other parameters in the validation cohort: BMI values (n = 199), hepatic TG evaluated by Folch method (n = 140; mg TG/g liver tissue),
glucose (n = 198), HDL (n = 167), platelets (n = 172), and total bilirubin (n = 171). (D) Leptin levels increased with steatosis severity in the validation cohort. The
x-axis represents the histological grade of steatosis, ranging from 0 to 3. There was a significant difference between grade 0 vs. 3 (n = 28, grade 0; n = 80, grade 1;
n = 49, grade 2; n = 48, grade 3). Leptin levels depicted as mean ± SEM. BMI, body mass index; CI, confidence interval; HDL, high-density lipoprotein; NAFL,
non-alcoholic fatty liver; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; NPV, negative predictive value; PPV, positive predictive value.
*p < 0.05; ***p < 0.001; ****p < 0.0001.
correlations were found between serum leptin and BMI or any
biochemical parameter.
In the validation cohort, leptin was higher again in NAFL
(39.74 ± 2.25 ng/ml) and NASH (43.72 ± 2.70 ng/ml) vs. non-
obese controls (6.21 ± 0.97 ng/ml; p < 0.0001) (Figure 1B).
Although a positive correlation was found between serum
leptin levels and BMI (p < 0.0001) (Figure 1C), no significant
differences were evident between non-obese and obese controls
(26.52 ± 5.82 ng/ml), suggesting that obesity might not be a
confounding factor (Figure 1B). Serum leptin showed a good
performance again when distinguishing controls (both non-
obese and obese) from NAFLD patients (both NAFL and
NASH), with AUROC = 0.83 (95%, CI 0.74–0.91; p < 0.0001).
Considering 25% disease prevalence and by applying the cutoff
value >9.33 ng/ml for NAFLD inclusion determined in the
discovery cohort, an overall accuracy of 0.60 (95% CI, 0.53–
0.67) was achieved, with sensitivity of 95% and specificity
of 48% (Figure 1B). Serum leptin positively correlated with
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hepatic TG content (p < 0.05), HDL (p < 0.01), platelets
(p < 0.01), and total bilirubin (p < 0.01) (Figure 1C). Curiously,
diabetic NAFLD patients had significantly lower leptin compared
with those who were non-diabetic (34.90 ± 2.87 vs. 45.39 ±
2.17 ng/ml; p < 0.01; Supplementary Figure 1), supported by
the negative correlation between leptin and fasting glucose (p <
0.05; Figure 1C). Leptin was increased in patients with severe
liver steatosis (stage 0 vs. 3, p < 0.05) (Figure 1D) and tended
to increase with lobular inflammation and hepatic ballooning,
while no significant differences were found with other co-
morbidities, fibrosis stage, or NAFLD-associated polymorphisms
(Supplementary Figure 1).
Given leptin’s association with hepatic fat accumulation, its
impact on the serum metabolic signatures of NAFLD patients
was further evaluated. Levels of circulating lipids and other
metabolites in NAFLD patients were compared between high/low
levels of circulating leptin. Higher serum leptin was associated
with a general increase in serum lipids, namely, FA (p < 0.05),
monounsaturated FA (p < 0.05), and FA containing palmitoleic
acid (16:1; p < 0.01) and linolenic acid (18:3; p < 0.001), while
diglycerides (DG) and TG were decreased (for TG, p < 0.05)
(Figure 2). Other lipid classes such as phosphatidylcholines
(PC), lysophosphatiylcholines, phosphatidylinositols (p < 0.05),
lysophosphatidylinositols, phosphatidylethanolamines (PE),
lysophosphatidylethanolamines (LPE), or sphingomyelin (SM;
p < 0.01) were increased in the serum of NAFLD patients with
high circulating leptin levels (Figure 2).
Overall, serum leptin predicts NAFLD, correlates with
serum lipid changes, and is a potentially valuable tool for
NAFLD diagnosis.
Adiponectin and Specific Lipid Species
Distinguish NASH
In the discovery cohort, adiponectin was similar among men and
women (6.55 ± 0.98 vs. 7.79 ± 1.04µg/ml) and significantly
lower inNASH vs. NAFL (non-obese controls: 8.51± 1.94µg/ml;
NAFL: 9.23 ± 0.85µg/ml; NASH: 4.45 ± 0.58µg/ml; p <
0.01) (Figure 3A). Serum adiponectin showed a good assay
performance when distinguishing NAFL vs. NASH (AUROC =
0.87; 95% CI, 0.77–0.99; p < 0.0001). This allowed us to establish
a cutoff value <7.32µg/ml for diagnosing NASH, with an overall
accuracy of 77%, sensitivity of 100%, and NPV (Figure 3A).
Additionally, the adiponectin serum levels negatively correlated
with the serummarkers of liver injury ALT (Spearman r=−0.46,
p < 0.01) and GGT (Spearman r =−0.42, p < 0.05).
In the validation cohort, adiponectin was lower in men
(4.4 ± 0.32 vs. 6.07 ± 0.29µg/ml, p < 0.0001) and, although
not significant, were lower in NASH (4.94 ± 0.27µg/ml)
vs. both non-obese (6.21 ± 0.97µg/ml) and obese (6.56
± 0.93µg/ml) controls or NAFL (6.22 ± 0.45µg/ml). In
this cohort, serum adiponectin was only able to distinguish
NAFL vs. NASH when NAFLD patients homozygous for
PNPLA3 wild-type allele c.444C were considered, even though
with a suboptimal performance (AUROC = 0.63; p < 0.05)
(Figure 3B). By applying the previously established cutoff value
of adiponectin <7.32µg/ml for NASH diagnosis, the PPV
FIGURE 2 | Serum lipidomic signatures associated with higher circulating
levels of leptin (dark gray) and adiponectin (light gray). Data presented as log2
of the lipid level fold change between patients with hormone levels higher than
the median vs. lower than the median. Leptin median level = 39.61 ng/ml;
higher, n = 99; lower, n = 99. Adiponectin median level = 4.84µg/ml; higher,
n = 95; lower, n = 99. Cer, ceramide; ChoE, cholesteryl ester; DG, diglyceride;
FA, fatty acid; LPC, lysophosphatidylcholines; LPE,
lysophosphatidylethanolamines; LPI, lysophosphatidylinositols; MUFA,
monounsaturated FA; PC, phosphatidylcholines; PE,
phosphatidylethanolamines; PI, phosphatidylinositols; PUFA, polyunsaturated
FA; SFA, saturated FA; SM, sphingomyelins; ST, steroids; TG, triglycerides;
16:0, palmitic acid; 18:3, linolenic acid; 20:4, arachidonic acid; 22:6n-3,
docosahexaenoic acid (DHA). *p < 0.05; **p < 0.01; ***p < 0.001.
and NPV were 49 and 71%, respectively. This AUROC value
was paralleled by AST/ALT ratio and only overcome by MRI
or Folch method AUROCs, however with lower specificity
values (Table 3). Curiously, NAFLD patients homozygous
for PNPLA3 risk allele c.444G presented significantly higher
adiponectin (GG vs. CC, p < 0.05; GG vs. CG, p < 0.0001;
Figure 3C). In the validation cohort, no differences were
found between adiponectin and fibrosis stage and ballooning
and lobular inflammation, neither for the presence/absence
of co-morbidities nor for the other NAFLD risk-associated
polymorphisms (Supplementary Figure 2). Adiponectin still
negatively correlated with AST (p < 0.01) and ALT (p < 0.001)
and positively correlated with total cholesterol (p < 0.05), HDL
(p < 0.001), and LDL (p < 0.01), regardless of PNPLA3 genotype
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FIGURE 3 | Adiponectin serum levels differentiate NAFL and NASH, but PNPLA3 genotype may be a confounding factor. (A) In the discovery cohort, the adiponectin
serum levels were significantly lower in NASH when compared to NAFL, presenting an AUROC value of 0.87 and very high sensitivity and NPV (non-obese control,
n = 8; NAFL, n = 19; NASH, n = 12). (B) In the validation cohort, adiponectin distinguishes NAFL from NASH only within PNPLA3 CC allele carriers, with an AUROC
value superior to 0.6 obese controls, n = 7; NAFL, n = 59, NASH, n = 47). (C) In the validation cohort, NAFLD patients with PNPLA3 GG genotype also showed
increased levels of adiponectin. The x-axis represents the three possible genotypes for rs738409 polymorphism: CC allele, n = 117; CG allele, n = 55; GG allele, n =
16). (D) Correlations between adiponectin serum levels and several parameters: AST and ALT serum levels (both n = 199), HDL and LDL serum levels (both n = 167),
total cholesterol levels (n = 168), and triglyceride serum levels (n = 168). (E) The adiponectin levels decreased with higher grades of steatosis. The x-axis represents
the histological grade of steatosis, ranging from 0 to 3. There was a significant difference between grade 2 vs. grade 1 and vs. grade 0 (n = 28, grade 0; n = 80,
grade 1; n = 49, grade 2; n = 48, grade 3). Adiponectin levels depicted as mean ± SEM. ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI,
confidence interval; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NAFL, non-alcoholic fatty liver; NASH, non-alcoholic steatohepatitis. *p < 0.05; **p <
0.01; ***p < 0.001.
(Figure 3D). Adiponectin decreased with severity of steatosis and
negatively correlated with serum TG (p < 0.05; Figures 3D,E).
Although not significant, higher serum adiponectin positively
correlated with serum lipid classes, except for DG, TG, and
steroids (Figure 2). Both PE and PC containing arachidonic
(20:4) or docosahexaenoic (DHA; 22:6n-3) acids were increased
in patients with high circulating adiponectin (p < 0.05 and
p < 0.01). Moreover, the serum levels of 147 metabolites
were significantly different between NAFL and NASH, of
which 35 were highly correlated with serum adiponectin
(Supplementary Table 2). Among those, nine TG were already
described as capable of distinguishing NAFL from NASH (16).
Sixty-five out of the 147 metabolites presented AUROC >0.60
and were considered for binomial regression analysis. This
allowed establishing a panel combining adiponectin and nine
serum lipids (mainly TG, PC, and SM), reaching an AUROC
value of ∼0.80 and an overall accuracy of 74% in distinguishing
NAFL from NASH in all patients, regardless of PNPLA3
genotype. When this panel was applied to homozygous carriers
of the PNPLA3 c.444C allele, the AUROC value increased to 0.83
and the accuracy to 80% (Table 4).
Overall, serum adiponectin inversely correlated with liver
injury markers and, when combined with nine specific lipids,
distinguished NAFL from NASH patients with high accuracy.






























TABLE 3 | Performance of serum adiponectin in the differential diagnosis of NAFL vs. NASH in patients homozygous for the wild-type allele CC in the PNPLA3 rs738409 polymorphism.
Cutoff AUROC (95% CI) Sensitivity (95% CI) Specificity (95% CI) Accuracy (95% CI) PPV (95% CI) NPV (95% CI) TP TN FP FN
Adiponectin <7.32µg/ml 0.63* (0.52–0.73) 0.85 (0.72–0.94) 0.29 (0.18–0.42) 0.54 (0.44–0.64) 0.49 (0.44–0.54) 0.71 (0.52–0.84) 40 17 42 7
AST/ALT <0.96 0.65** (0.55–0.76) 0.89 (0.77–0.96) 0.49 (0.36–0.63) 0.67 (0.75–0.76) 0.59 (0.52–0.66) 0.85 (0.70–0.93) 42 28 29 5




>42.85 mg/g 0.75*** (0.63–0.87) 0.83 (0.67–0.94) 0.59 (0.42–0.74) 0.70 (0.59–0.80) 0.64 (0.54–0.72) 0.80 (0.65–0.90) 30 24 17 6
Applied in validation cohort. Adiponectin; n = 106; AST/ALT, n = 104; MRI, n = 67; hepatic TG content evaluated by Folch method, n = 77. NASH is considered positive if the levels of each parameter are superior or inferior to the
cutoff value as indicated.
AST/ALT, aspartate aminotransferase to alanine aminotransferase ratio; CI, confidence interval; FN, false negative; FP, false positive; MRI, magnetic resonance imaging; NAFL, nonalcoholic fatty liver; NASH, nonalcoholic steatohepatitis;
NPV, negative predictive value; PPV, positive predictive value; TN, true negative; TP, true positive.
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
TABLE 4 | Performance of serum lipids and combination panel with serum adiponectin in the differential diagnosis of NAFL vs. NASH.
Cutoff AUROC (95% CI) Sensitivity (95% CI) Specificity (95% CI) Accuracy (95% CI) PPV (95% CI) NPV (95% CI) TP TN FP FN
TG(44:0) >0.25 0.72* (0.65–0.79) 0.60 (0.49–0.70) 0.75 (0.65–0.83) 0.67 (0.60–0.74) 0.70 (0.61–0.77) 0.65 (0.59–0.71) 54 68 23 36
TG(49:2) >0.71 0.70* (0.63–0.78) 0.71 (0.61–0.80) 0.58 (0.47–0.69) 0.65 (0.57–0.72) 0.63 (0.56–0.69) 0.67 (0.59–0.75) 64 53 38 26
TG(51:3) >1.02 0.61* (0.54–0.69) 0.61 (0.50–0.71) 0.56 (0.45–0.66) 0.59 (0.51–0.66) 0.58 (0.51–0.65) 0.59 (0.52–0.67) 55 51 40 35
TG(52:1) >0.85 0.75** (0.68–0.82) 0.79 (0.69–0.87) 0.59 (0.49–0.70) 0.69 (0.62–0.76) 0.66 (0.59–0.72) 0.74 (0.65–0.81) 71 54 37 19
TG(53:1) >0.48 0.74* (0.67–0.81) 0.89 (0.81–0.95) 0.49 (0.39–0.60) 0.69 (0.62–0.76) 0.63 (0.58–0.68) 0.82 (0.71–0.89) 80 45 46 10
TG(54:0) >0.38 0.68* (0.61–0.76) 0.72 (0.62–0.81) 0.57 (0.46–0.67) 0.65 (0.57–0.72) 0.63 (0.56–0.69) 0.68 (0.59–0.75) 65 52 39 25
TG(60:3) >0.58 0.60 (0.50–0.66) 0.70 (0.59–0.79) 0.47 (0.37–0.58) 0.59 (0.51–0.66) 0.57 (0.51–0.62) 0.61 (0.52–0.70) 63 43 48 27
PC(0:0/14:0) >0.22 0.70* (0.62–0.77) 0.80 (0.70–0.88) 0.51 (0.40–0.61) 0.65 (0.58–0.72) 0.62 (0.56–0.67) 0.72 (0.62–0.80) 72 46 45 18
SM(38:0) >1.16 0.71* (0.63–0.78) 0.74 (0.64–0.83) 0.64 (0.53–0.74) 0.69 (0.62–0.76) 0.67 (0.60–0.73) 0.72 (0.63–0.79) 67 58 33 23
Adiponectin + 9 lipids - 0.796** (0.73–0.86) 0.71 (0.61–0.80) 0.77 (0.67–0.85) 0.74 (0.67–0.80) 0.75 (0.67–0.82) 0.73 (0.66–0.79) 64 70 21 26
Adiponectin + 9 lipids
(PNPLA3 rs738409 CC)
- 0.832** (0.75–0.91) 0.70 (0.55–0.83) 0.88 (0.77–0.95) 0.802 (0.71–0.87) 0.83 (0.70–0.91) 0.79 (0.70–0.85) 33 52 7 14
Applied in the validation cohort, n = 181; PNPLA3 rs738409 CC carriers, n = 106. NASH is considered as positive if the levels of each parameter are superior or inferior to the cutoff value as indicated; for adiponectin, <7.32µg/ml.
p-values corrected with Benjamini–Hochberg procedure, assuming 5% false discovery rate.
CI, confidence interval; FN, false negative; FP, false positive; NAFL, nonalcoholic fatty liver; NASH, nonalcoholic steatohepatitis; NPV, negative predictive value; PC, phosphatidylcholine; PPV, positive predictive value; TG, triglyceride;
TN, true negative; TP, true positive; SM, sphingomyelin.
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IGF-1 Predicts Advanced Fibrosis in NAFLD
IGF-1 was higher in men in both cohorts (discovery cohort:
152.08 ± 20.78 vs. 81.04 ± 12.24 ng/ml, p < 0.01; validation
cohort: 126.5 ± 6.78 vs. 103.4 ± 3.87 ng/ml, p < 0.01). In
the discovery cohort, the IGF-1 levels decreased in NAFL
(109.95 ± 16.55 ng/ml) and NASH (113.19 ± 17.39 ng/ml)
when compared to non-obese controls (167.42 ± 17.55 ng/ml),
although not significantly. In the validation cohort, there were
no significant changes in IGF-1 between non-obese controls
(115.75 ± 15.69 ng/ml), obese controls (105.83 ± 15.62 ng/ml),
NAFL (122.30 ± 6.05 ng/ml), and NASH (103.50 ± 3.98 ng/ml),
although an inverse correlation with BMI was observed (n =
199; Spearman r = −0.1647; 95% CI, 0.30-−0.02; p < 0.05)
(Figures 4A,B). In agreement, in the validation cohort, there
were also no significant differences in IGF-1 relating to liver
steatosis, lobular inflammation, or hepatocyte ballooning severity
(Supplementary Figure 3), yet IGF-1 was significantly lower
in NAFLD patients with advanced fibrosis (F3–4; p < 0.05)
(Figure 4C). By establishing a cutoff value of IGF-1 inferior
to 98.83 ng/ml for the presence of advanced fibrosis, 70%
sensitivity, 61% specificity, and 63% overall accuracy were
obtained (Figure 4C and Table 5). Overall, IGF-1, as well as
the pre-established biomarker fibrosis panels APRI, Fib-4, and
NFS, displayed a suboptimal performance in F0–2 vs. F3–4
discrimination. However, by combining serum IGF-1, ferritin,
and INR, the discriminatory power was significantly improved,
resulting in AUROC value of 0.81 and overall accuracy of
93%, considering the ∼10% prevalence of advanced fibrosis
in this cohort (Table 5). Importantly, besides a robust NPV,
this panel displayed 71% PPV value, contrasting with the low
PPV values from APRI, Fib-4, and NFS. Circulating IGF-
1 did not correlate with other parameters or co-morbidities
(Supplementary Figure 3).
Serum metabolomic analysis showed that higher IGF-1
was associated with an overall increase in main lipid classes,
significant for LPE (p < 0.05), PC containing arachidonic acid
(20:4; p < 0.05), diacylglycerophosphocholine (p < 0.05), and
monoacylglycerophosphoethanolamine (p < 0.05) (Figure 4D).
Moreover, 26 specific serum metabolites were able to distinguish
advanced fibrosis, with several bile acids increased in advanced
fibrosis, and both cholic acid and PC (17:0/18:2) positively
correlated with IGF-1 (Supplementary Table 3).
IGF-1 altogether could identify advanced fibrosis, particularly
in combination with INR and ferritin, and correlates with serum
lipid changes associated with fibrosis.
DISCUSSION
The strong association between obesity and NAFLD, parallel
with the continuous rise in the prevalence of obesity, prompts
a more detailed study of the role of adipokines and other
hormones as potential non-invasive biomarkers for NAFLD
(1). Therefore, we measured serum leptin, adiponectin, and
IGF-1 in two independent cohorts, comprising both biopsy-
proven healthy-liver controls as well as obese NAFL and NASH
patients. In the discovery cohort, the serum hormones were
correlated with clinical and histological information, including
NAS, fibrosis stage, and biochemical parameters. Results were
then validated in a second cohort, which further allowed us
to explore the role of obesity as a confounding factor by
including a control group of obese healthy-liver individuals.
Additionally, in this validation cohort, hormone serum levels
were correlated with liver imaging, co-morbidities, and NAFLD
risk-associated polymorphisms. For a subset of patients, serum
metabolomic analysis was also performed. This strategy showed
that particularly leptin and adiponectin can be potential diagnosis
and stratification biomarkers in NAFLD. The role of these
two adipokines in NAFLD pathophysiology, diagnosis, and
even treatment has attracted significant attention despite the
controversial results.
Leptin is a 16-kDa pro-inflammatory adipokine produced by
adipocytes. Serum leptin levels reflect total body mass. Leptin
may exert an anti-steatotic action in early NAFLD by promoting
FA oxidation and decreased lipogenesis and a pro-inflammatory
and pro-fibrotic action at later disease stages by increasing
hepatic reactive oxygen species generation, pro-inflammatory
cytokine release, and enhanced fibrinogenesis (28, 29). Previous
reports have generally found increased serum leptin in NAFLD
patients (12, 29, 30). Still the role of obesity as a bias remains
poorly explored. Our results in the discovery cohort showed that
leptin accurately identified NAFLD patients, where there was
no correlation with BMI. Moreover, in the validation cohort,
although leptin levels positively correlated with BMI, they were
higher in NAFL and NASH compared with both non-obese and
obese controls, suggesting that the association between NAFLD
and leptin is more robust than the effect of obesity on leptin
levels. In this cohort, serum leptin showed again a very good
performance as a potential biomarker to distinguish NAFLD
patients from healthy individuals. After applying the cutoff value
of leptin at >9.33 ng/ml for diagnosing NAFLD in the validation
cohort, despite having a lower general accuracy, it still presented
sensitivity, specificity, and NPV values far superior than those
previously reported (31, 32).
In turn, adiponectin, a 30-kDa protein mainly secreted
by adipose tissue, is the most well-studied adipokine in the
pathogenesis of NAFLD (30, 33). It is considered to have anti-
inflammatory, anti-steatotic, and anti-fibrotic effects. In the
liver, adiponectin prevents lipid accumulation by promoting
FA oxidation via peroxisome proliferator-activated receptor
alpha (33). Adiponectin also downregulates pro-inflammatory
cytokines produced by Kupffer cells and hepatic stellate cells,
thus inhibiting their transformation into myofibroblasts and
consequently decreasing liver fibrosis (30, 34–36). Several reports
have shown a reverse relation between adiponectin circulating
levels and body fat mass and its decrease in obesity, type
2 diabetes, insulin resistance, and dyslipidemia (30, 34). A
meta-analysis showed that adiponectin decreases in healthy
controls compared to NAFL, and in the latter compared
to NASH (37). However, there is significant heterogeneity
among studies, and the importance of including biopsy-
proven healthy controls is underlined; most differences in
adiponectin between individuals with NAFLD and controls
were observed when the controls were not subjected to liver
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FIGURE 4 | IGF-1 serum levels correlated with liver fibrosis score. (A) In the discovery cohort, the IGF-1 serum levels were slightly lower in NASH patients compared
to NAFL and non-obese contros. (B) No significant differences in IGF-1 levels were found among controls and patients with NAFLD in the validation cohort. (C) In the
validation cohort, NAFLD patients with advanced fibrosis presented significantly lower levels of IGF-1. The x-axis represents fibrosis score dichotomy: none to
moderate fibrosis (F0-2; n = 184) and advanced fibrosis to cirrhosis (F3-4; n = 19). IGF-1 alone presents an AUROC value of 0.67 when distinguishing F0-2 vs. F3-4.
(D) Serum lipidomic signature associated with higher IGF-1 circulating levels. Data presented as log2 of the fold change between higher vs. lower than the median
IGF-1 level (103.65 ng/ml). Higher, n = 97; lower, n = 97. IGF-1 levels depicted as mean ± SEM. Cer, ceramide; ChoE, cholesteryl ester; CI, confidence interval; DAPC,
diacylglycerophosphocholine; DG, diglyceride; FA, fatty acid; IGF-1, insulin-like growth factor 1; LPC, lysophosphatidylcholines; LPE, lysophosphatidylethanolamines;
LPI, lysophosphatidylinositols; MAPE, monoacylglycerophosphoethanolamine; MUFA, monounsaturated FA; NAFL, non-alcoholic fatty liver; NASH, non-alcoholic
steatohepatitis; NPV, negative predictive value; PPV, positive predictive value; PC, phosphatidylcholines; PE, phosphatidylethanolamines; PI, phosphatidylinositols;
PUFA, polyunsaturated FA; SFA, saturated FA; SM, sphingomyelins; ST, steroids; TG, triglycerides; 20:4, arachidonic acid. *p < 0.05.
biopsy (37). In the discovery cohort, adiponectin presented
a very promising performance in distinguishing NAFL vs.
NASH. However, when tested in the larger validation cohort,
adiponectin only presented a fair discriminatory power in
this stratification when homozygous carriers of the PNPLA3
c.444C allele were considered. Importantly, the discriminatory
power of adiponectin regarding NAFL vs. NASH patients was
improved when combined with nine specific lipids. Previously,
others have shown that combining adiponectin with homeostatic
model assessment for insulin resistance and type IV collagen
7S increased the assay sensitivity from 68 to 94% in early-stage
NASH prediction (38), while combining adiponectin, resistin,
and cleaved cytokeratin-18 predicted NASH with an AUROC
of 0.90 (39). Similar approaches combining adiponectin serum
levels with a panel of serum lipids, mainly PC species, have been
shown to discriminate between healthy individuals, NAFL, and
NASH with high accuracy (40). Curiously, previous observations
showed that NAFLD patients homozygous for the c.444G allele
presented decreased adiponectin (41); however, the opposite was
observed here. Nonetheless, these results could explain how
this subgroup of NAFLD patients has an improved response to
treatment and lifestyle interventions, including bariatric surgery,
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when compared to CG and CC carriers (42). Additionally, we
showed that lower levels of serum adiponectin associated with
higher AST and ALT, thus suggesting a role of adiponectin
in preventing liver damage. Overall, our observations suggest
that adiponectin might be a valuable tool in NAFL vs. NASH
stratification; however, its role as a biomarker in NAFLD can
be challenged by risk-conferring genetic variants, such as the
PNPLA3 c.444G allele, and can benefit from combination panels,
such as the one presented comprising serum lipids.
In fact, NAFLD has been associated with increased lipids
in both liver tissue and plasma. Here we observed that higher
circulating leptin associated with increased serum lipid profile
and increased hepatic steatosis as assessed by histology and
imaging. Similarly, higher circulating adiponectin associated with
an increased serum lipid profile. The fact that adiponectin is
inversely correlated with liver fat contents, as evaluated by MRI,
might suggest a protective action for adiponectin by promoting
lipid removal from the liver into circulation. For instance,
higher adiponectin associated with higher serum PE containing
arachidonic acid (C20:4n-6), while lower liver levels of this acid
have been observed in NAFLD due to active conversion into
pro-inflammatory prostaglandins (13). Furthermore, increased
serum PE containing DHA also followed higher adiponectin.
DHA, whose lower levels have been associated with both NAFL
and NASH, is believed to have anti-inflammatory and metabolic
effects and to be able to lower liver TG (13, 14, 43, 44). This might
also explain why higher adiponectin inversely correlates with TG
as measured by blood biochemistry and serum metabolomics.
In turn, IGF-1, mainly produced in the liver in response
to growth hormone stimulation, is known to regulate insulin
sensitivity and decrease hepatic TG accumulation in the liver
(45). While a few clinical studies have associated low serum
IGF-1 with increased severity of steatosis (46, 47) or lobular
inflammation (48), our results and those of others (49) failed
to show any association. On the other hand, clinical studies
are consensual when reporting low serum IGF-1 association
with the severity of fibrosis (46, 48–50). In fact, in vitro and in
vivo studies showed that IGF-1 can induce cellular senescence
and hepatic stellate cell inactivation through a p53-dependent
manner, thus improving experimental fibrosis (51). Accordingly,
here we showed that patients with NAFLD and advanced fibrosis
presented significantly lower serum IGF-1. More importantly,
we found that the 63% accuracy of serum IGF-1 alone in
distinguishing low/mild fibrosis from advanced fibrosis is further
improved to 93% if IGF-1 is combined with ferritin and INR.
These results are very similar to those determined for the
Enhanced Liver Fibrosis (ELF) test, recommended by the NICE
guidelines for the evaluation of fibrosis in NAFLD (9). A poor
PPV value has still been reported for the generality of fibrosis
tests, including ELF (52). The panel here proposed displayed high
PPV value, being matched by the recent Hepamet fibrosis scoring
system where a PPV of 76% was achieved (53). Recent reports
suggest that IGF-1 biodisponibility might be decreased during
disease progression toward NASH and liver fibrosis and advance
IGF-1/intact IGFBP3 ratio as a fibrosis predictor (54). Moreover,
IGF-1 might associate with a fibrosis-specific serum metabolite
profile, where many bile acids were found increased in advanced
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fibrosis, namely, cholic acid, which also correlated with serum
IGF-1. Increased levels of many bile acids, including cholic acid,
have already been associated with liver fibrosis (55).
Inclusion of a patient group comprising lean-NAFLD would
allow further inquiries on adipokines as NAFLD biomarkers,
particularly for leptin. It is also recognized that the number of
healthy non-obese controls is relatively small, mostly due to the
difficulty in obtaining biopsies from healthy-liver individuals.
Lastly, the performance of the proposed biomarker panels
comprising serum adiponectin and lipids for NAFL vs. NASH
stratification and serum IGF-1 with INR and ferritin for
identification of advanced fibrosis should be prospectively tested
in a different cohort.
CONCLUSION
In conclusion, we suggest that serum leptin can identify NAFLD
without obesity as a confounding factor, whereas adiponectin
combined with specific serum lipids might be advantageous
for NAFL vs. NASH stratification. In turn, IGF-1, together
with ferritin and INR, could embody a valuable biomarker
panel to identify advanced fibrosis, which could be easily
implemented in clinics and presents a better PPV than the
regularly used algorithms. Serum metabolomics correlate with
hormone levels and offer new opportunities for improved non-
invasive biomarker panels.
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